BAY1082439

BAY1082439 is an orally bioavailable, selective PI3Kα/β/δ inhibitor. BAY1082439 also inhibits mutated forms of PIK3CA. BAY1082439 is highly effective in inhibiting Pten-null prostate cancer growth[1][2].

Product Specifications

CAS Number

[1375469-38-7]

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

Apoptosis; PI3K

Type

Reference compound

Related Pathways

Apoptosis; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bay1082439.html

Purity

98.02

Solubility

0.1 M HCl : 16.67 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 5 mg/mL (ultrasonic; adjust pH to 5 with HCl)

Smiles

O=C(C1=CC=CN=C1C)NC2=NC3=C(C=CC(OC[C@H](O)CN4CCOCC4)=C3OC)C5=NCCN25

Molecular Formula

C25H30N6O5

Molecular Weight

494.54

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Ningshu Liu, et al. Abstract 2799: BAY 1082439, a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. Abstract nr 2799. doi:1538-7445.AM2012-2799.|[2]Yongkang Zou, et al. Co-Targeting the Cell Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3Kα/β/δ inhibitor BAY1082439. Mol Cancer Ther. 2018 Oct;17 (10) :2091-2099.